Fibryga was found to be noninferior to cryoprecipitate based on the total number of units of allogeneic blood products administered during the first 24 hours after termination of cardiopulmonary ...
LACHEN, Switzerland--(BUSINESS WIRE)--Octapharma today announced that the Swiss Agency for Therapeutic Products, Swissmedic, granted marketing authorization to its new fibrinogen concentrate product ...
PARAMUS, N.J., Jan. 7, 2026 /PRNewswire/ -- Octapharma USA, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved a new 2-gram presentation of Fibryga ®, Fibrinogen (Human ...
Fibrinogen plays an important role in coagulation and blood clotting in emergency and surgical settings. Fibrinogen is the first coagulation factor to drop to critically low levels during severe ...
Octapharma has received approval from the US Food and Drug Administration (FDA) for a new 2-gram (g) formulation of Fibryga for use in patients with acquired fibrinogen deficiency (AFD). The approval ...
American Red Cross Declares Nation’s First-Ever National Blood Crisis with COVID-19 Continuing to Overwhelm Hospitals PARAMUS, N.J.--(BUSINESS WIRE)--Patient blood management strategies have become ...
Octapharma has announced the publication of new data demonstrating that the fibrinogen concentrate fibryga is an effective alternative to cryoprecipitate for patients with severe bleeding during ...
PARAMUS, N.J, Aug. 1, 2024 /PRNewswire/ -- Octapharma USA, Inc. has announced the expanded approval of fibryga(R) , Fibrinogen (Human) Lyophilized Powder for Reconstitution, for fibrinogen replacement ...
PARAMUS, N.J, Aug. 1, 2024 /PRNewswire/ -- Octapharma USA, Inc. has announced the expanded approval of fibryga ®, Fibrinogen (Human) Lyophilized Powder for Reconstitution, for fibrinogen replacement ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results